BACK

Ross Cohen

Ross Cohen

Associate

New York Office  |  ross.cohen@torreya.com   |   212.257.5812

Ross Cohen is an Associate on the Capital Markets team at Torreya. He provides transaction support on funding deals that involve private and public equity, private debt, and royalty-backed debt and monetizations. Ross also has experience working on strategic transactions, including asset divestitures, restructurings, mergers, and company sales.

Before joining Torreya in 2014, Ross was a Business Development Director at Board Studios, where he developed and executed strategic business partnerships and strategies, and at Barclays Capital, where he focused on corporate development and strategy.

Ross received a B.B.A. in finance from George Washington University.

Selected Transactions

BIO-PHARM
Sale to
torrent pharma
Undisclosed
January 2018
Crown Laboratories
Sale of
majority equity stake to
Hildred
Undisclosed
December 2017
CombiMatrix
Merger with
Invitae Corporation
$34.9 million
November 2017
Wafergen Biosystems
Company sale to
Takara
$35.9 million
March 2017
Topix Pharmaceuticals
Sale of majority stake to
New Mountain Capital
Undisclosed
July 2016
EyePoint Pharmaceuticals
Debt financing for acquisition of Icon Biosciences from
SWK Holdings
$20 Million
March 2018
Undisclosed Physical Therapy Practice
Majority recap by
Hildred Capital Partners
Undisclosed
March 2018
Midatech
Loan agreement with
Midcap Financial
$15 Million
January 2018
XOMA
License of
Gevokizumab and
certain associated IP to
Novartis
$31 million upfront
August 2017
Clarus Ventures
Acquisition of phase III royalty interest
Undisclosed
Undisclosed
May 2017
XOMA
Sale of royalties to
Healthcare Royalty Partners
$22 million
December 2016
Opiant Pharmaceuticals
Sale of royalties to
SWK Holdings
$17.5 million
December 2016
SciDose
Partial sale of royalty
and milestones
Undisclosed
$40 million
September 2016
IntelgenX
Partial royalty and milestone sale to
SWK Holdings
$6 million
August 2016
Academic Investor
Sale of
phase II enzyme replacement royalty
Undisclosed
Undisclosed
August 2016
HealthCare Royalty Partners
Royalty-backed
acquisition financing
for undisclosed
spec pharma
Undisclosed
$100 million
February 2016
Amerigen
Senior term loan
Undisclosed
$15 million
December 2015
XOMA
Sale of
biologics manufacturing
facilities to
Agenus
$5 million in cash +
$1 million in stock
November 2015
XOMA
License of global rights
for Anti-TGF-beta
antibody program to
Novartis
Up to $517 million
October 2015
Crown Laboratories
Debt financing from
Hayfin Advisors
$20 million
September 2015